RESEARCH ARTICLE

mTOR Inhibition Attenuates Dextran Sulfate Sodium-Induced Colitis by Suppressing T Cell Proliferation and Balancing TH1/TH17/Treg Profile

Shurong Hu1☯, Mengmeng Chen1☯, Yilin Wang2, Zhengting Wang1, Yaofei Pei3, Rong Fan1, Xiqiang Liu4, Lei Wang1, Jie Zhou1, Sichang Zheng1, Tianyu Zhang1, Yun Lin1, Maochen Zhang1, Ran Tao4*b, Jie Zhong1*a

1 Department of Gastroenterology, Ruijin hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China, 2 Department of Surgery, Cancer hospital, Fudan University, Shanghai, PR China, 3 Department of Surgery, Ruijin hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China, 4 Department of Hepatobiliary-Pancreatic Surgery, Zhejiang Provincial People’s Hospital, Hangzhou, Zhejiang Province, PR China

☯ These authors contributed equally to this work.
*b Current address: Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, PR China
*a Current Address: Department of Hepatobiliary-Pancreatic Surgery, Zhejiang Provincial Peoples’ Hospital (ZJPPH), Hangzhou, Zhejiang Province, PR China

* jimmyzj64@hotmail.com (JZ); taohdac@yahoo.com (RT)

Abstract

It has been established that mammalian target of Rapamycin (mTOR) inhibitors have anti-inflammatory effects in models of experimental colitis. However, the underlying mechanism is largely unknown. In this research, we investigate the anti-inflammatory effects of AZD8055, a potent mTOR inhibitor, on T cell response in dextran sulfate sodium (DSS)-induced colitis in mice, a commonly used animal model of inflammatory bowel diseases (IBD). Severity of colitis is evaluated by changing of body weight, bloody stool, fecal consistency, histology evaluation and cytokine expression. We find that AZD8055 treatment attenuates DSS-induced body weight loss, colon length shortening and pathological damage of the colon. And AZD8055 treatment decreases colonic expression of genes encoding the pro-inflammatory cytokines interferon-γ, interleukin (IL)-17A, IL-1β, IL-6 and tumor necrosis factor (TNF)-α and increases colonic expression of anti-inflammatory cytokines IL-10. We show that AZD8055 treatment decreases the percentages of CD4+ T cells and CD8+ T cells in spleen, lymph nodes and peripheral blood of mice. We also find that AZD8055 treatment significantly reduces the number of T helper 1 (TH1) cells and TH17 cells and increases regulatory T (Treg) cells in the lamina propria and mesenteric lymph nodes. Furthermore, we demonstrate that AZD8055 suppresses the proliferation of CD4+ and CD8+ T cells and the differentiation of TH1/TH17 cells and expands Treg cells in vitro. The results suggest that, in experimental colitis, AZD8055 exerts anti-inflammatory effect by regulating T helper cell polarization and proliferation.
Introduction

Inflammatory bowel diseases (IBD) which consist of Crohn’s disease (CD) and ulcerative colitis (UC), are chronic heterogeneous intestinal disorders, which remain clinically challenging [1, 2]. Currently, the drugs for IBD patients are limited. The precise etiology of IBD remains unknown, although it is generally accepted that it result from an overactive immune response to commensal bacteria within the gut in genetically predisposed individuals [3].

Helper T cells have a significant role in IBD pathogenesis [4]. TH1, TH2, TH17 and regulatory T cells (Tregs) form an important quarter of helper T cells [5, 6]. Studies have been shown that TH1, TH2, and TH17 cells were essential for defenses against excessive entry of microorganisms [7, 8]. Intestinal immune homeostasis depends on the regulation and balance of these T cell subgroups. It has been shown that deregulated overexpansion and activation of effector cells in relation to regulatory T cells can lead to intestinal inflammation like IBD [9, 10].

The T cell transfer induced colitis has been used to study T cell response in IBD. In this study, CD4+CD45RBhi T cells are transferred into immune-deficient mice. Since this model depends on genetically compromised mice and an unbalance of naïve and Treg cells which is not seen in wild type mice, it does not reflect the immunological courses of the development of pathogenic T cells in healthy animals [11–13]. On the other hand, DSS-induced colitis model is a classic and stable model of murine colitis, which can be used in all backgrounds of mice. Many drugs used in IBD patients are also available for this model [14–16]. Previous studies have shown that DSS-induced colitis is often not considered as a good model for T cell involvement, since it is chemical damage model which can be induced without the help of T cells. However, recent studies show that T cells especially pro-inflammatory, antigen-specific CD4+ T cells accumulate at the site of inflammation, and do progress during DSS-induced colitis model, suggesting that DSS model can be used to study T cell development during intestinal inflammation [17–19].

Mammalian target of Rapamycin (mTOR) is a protein kinase that regulates cell survival, cell growth, cell proliferation and autophagy. Besides its crucial role in tumorigenesis, recent studies show that mTOR participates in adjusting adaptive immune response and modulating CD4+ or CD8+ T cell polarization, as well as increasing the percentage of Treg cells [20–22]. Farkas et al showed that Rapamycin, an mTOR inhibitor, reduced leukocyte migration as effectively as immunosuppressant cyclosporine A (CsA) in DSS-induced murine colitis [23]. Matsuda et al found that Everolimus, a Rapamycin analog, prevented colitis in interleukin-10(IL-10)−/− model by decreasing the percentage of CD4+ T cells in the colonic mucosa and reducing IFN-γ production [24].

mTOR functions in two multi-protein complexes, mTORC1 and mTORC2. mTORC1 is suppressed by Rapamycin, but Rapamycin can’t block mTOR activity completely due to its inability to influence mTORC2 directly [25, 26]. On the other hand, ATP-competitive mTOR inhibitor AZD8055 targets the ATP site and inhibits any mTOR-containing complex [27]. AZD8055 not only inhibits phosphorylation of the mTORC1 substrates p70S6K and 4E-BP1, but also phosphorylation of the mTORC2 substrates AKT and downstream protein [28]. In spite of the emerging role of RAPA-resistant mTOR in immune cell function, the effect of AZD8055 on T cells has not been fully studied. In this study, we investigate the effect of AZD8055 in DSS-induced colitis. We find that AZD8055 attenuates DSS-induced colitis by inhibiting T-cell proliferation and balancing TH1/TH17/Treg profile.

Materials and Methods

Ethics Statement

All experimental procedures were performed in accordance with the criteria issued by the Chinese ethics committee for animal studies, formulated by the Ministry of Science and Technology.
of the People’s Republic of China. The animal protocols were examined and approved by the 
Ethical Committee on Animal Experiments at Shanghai Ruijin Hospital. All endeavors were 
made to alleviate suffering.

Mice
6–8 weeks old male C57BL/6 mice were gained from Shanghai Laboratory Animal Center 
(SLAC) and housed under specific pathogen-free environment in the Research Center for 
Experimental Medicine of Shanghai Ruijin Hospital. All animal studies were authorized and 
handled according to the guidelines of the Ethics Committee of Ruijin Hospital.

Reagents
AZD8055 was purchased from Selleck (China). It was dissolved in dimethyl sulfoxide (DMSO) 
and prepared as 10mM stock solutions and stored at -20°C for in vitro studies. For in vivo 
administration, AZD8055 solution was diluted in sterile emulsifiers.

Induction of Dextran Sodium Sulfate (DSS) Colitis and assessment of 
ae colitis
Mice were randomly divided into three groups, Wild type (WT), DSS, DSS+AZD8055 (n = 8 in 
each group). For acute colitis, mice were subjected to 4% (w/v) DSS (MW 36,000–50,000, MP 
Biomedical) in their drinking water for 7 (day0–6) days. Mice were monitored daily by change 
of body weight, gross rectal bleeding, and stool consistency. The disease activity index score 
(DAI) was described previously (Table 1) [29]. Mice were treated daily intra-peritoneally (i.p.) 
with 10mg/kg AZD8055 or emulsifier as control from day 0 to day 6 and were sacrificed on 
day 7.

Histological examination
The colons were embedded in paraffin and stained with hematoxylin-eosin (H&E). To evaluate 
the histological inflammation, we adopted the histological damage score: edema; crypt loss; 
erosion/ulceration and mono- and poly-morphonuclear cells infiltration. The degree of colon 
inflammation scored from 0 to 20 [30]. The analysis was performed by two investigators who 
were blinded to the experiment.

Preparation of lamina propria (LP) lymphocytes
LP lymphocytes were isolated according to previously described study [31]. Briefly, the intestines 
were opened longitudinally, washed with PBS to remove stool, and shaken in Hank’s Balanced 
Salt Solution (HBSS) supplemented with 4% FBS and 5mM EDTA (Sigma-Aldrich) at

| Weight loss(%) | Occult blood    | Stool consistency | Score |
|----------------|-----------------|-------------------|-------|
| <1             | Negative        | Normal            | 0     |
| 1–5            | Haemoccult positive | Soft stool     | 1     |
| 5–10           |                  | Loose stool       | 2     |
| 10–20          |                  | Muddy stool       | 3     |
| >20            | Gross bleeding  | Diarrhea          | 4     |

Five grades of weight loss and stool consistency and three grades of occult blood.

doi:10.1371/journal.pone.0154564.t001
37°C for 25 min. This procedure was to remove epithelial cells and intraepithelial lymphocytes. The colon fragments were then incubated with RPMI 1640 supplemented with 4% FBS and 1mg/ml collagenase type IV (R&D) and Dnase I (Sigma-Aldrich) at 37°C for 25 min with stirring. The digested tissues were pooled together and separated on a 40/80% discontinuous Percoll gradient (GE Healthcare). The gradient separation was centrifuged at 2500rpm for 25 min at room temperature. Lamina propria mononuclear cells were collected at the interface of the Percoll gradient, washed, and suspended in RPMI 1640 containing 4% FBS.

Establishment of T cell Proliferation and Differentiation in vitro

Splenocytes and lymph nodes were isolated and prepared as mononuclear cells from mice. CD4+ T cells and CD8+ T cells were respectively negatively selected using the CD4+ T cell Isolation kit (Miltenyi) and CD8+ T cell Isolation kit (Miltenyi). In order to analysis T cell proliferation, CD4+ T cells and CD8+ T cells were labeled with carboxyfluorescein succinimidyl ester (CFSE; Invitrogen). Cells were stimulated with mouse antibody CD3/CD28 (Invitrogen) at 2μg/ml for 3 days in the presence of AZD8055 at the indicated concentrations and were evaluated by flow cytometry. In order to analysis T cell differentiation into TH1, TH17 or Treg cells, naive T cells were sorted by CD4+CD62L+ T cell Isolation kit II (Miltenyi). Naive T cells were labeled with CFSE and stimulated with anti-CD3 (2 μg/mL), and anti-CD28 (2 μg/mL) antibodies under TH0(40 U/mL mouse IL-2), TH1 (40μg/mL anti-mouse IL-4, 40 ng/mL mouse IL-12), TH17 (50 ng/mL mouse IL-6, 2.5 ng/mL mouse TGF-β, 10 μg/mL anti-mouse IFN-γ, 20 ng/mL mouse IL-23, 10μg/mL anti-mouse IL-4) or Treg conditions(2 ng/mL mouse TGF-β) for 4 days in the presence of AZD8055 at specified concentrations and were evaluated by flow cytometry.

Flow cytometry

To quantify the percentage of CD4 and CD8 positive cells, mononuclear cells from spleen, mesenteric lymph node and lamina propria were washed and incubated with anti-CD3-APC, anti-CD4-FITC, anti-CD8-PE (ebioscience, San Diego, CA). To determine the percentage of TH1 and TH17 cells, mononuclear cells were stimulated with PMA (50ng/mL, sigma) and Ionomycin (1μg/mL, Tocris) and BFA (1:1000, eBioscience) for 6 hours. Cells were then washed and stained with anti-CD4-FITC. Following CD4 staining, cells were blocked, fixed, permeabilized and stained with anti-IFN-γ-APC or anti-IL-17-PE-Cy7. To detect the percentage of Treg cells, mononuclear cells were stained with anti-CD4-FITC and anti-CD25-APC and then fixed/permeabilized and incubated with anti-Foxp3-PE. All labeled cells were detected using FCM on the FACScan Flow Analyzer. The results were evaluated with FlowJo7.6 software [32, 33].

Quantitative reverse-transcription polymerase chain reaction analysis

Total RNA from colonic samples were extracted by TRIzol® Reagent (Invitrogen Life Technologies) and were reverse transcribed using oligo (dT) primers (Takara) in accordance with the manufacturer’s instructions. Real-time polymerase chain reaction (PCR) was performed on QuantiTect SYBR Green PCR Kit. The expressions of target gene were analyzed by their ratios to the house keeping gene hypoxanthine-guanine phosphoribosyl transferase (HPRT). The sequence of target genes primer sets were listed in Table 2.

Statistical Analysis

Statistical analysis was determined by t-test and one-way analysis of variance. Differences with P<0.05 were considered statistically significant.
Results

1. AZD8055 attenuates the development of intestinal inflammation

In assessing the role of AZD8055 in the development of colitis, we used 4% DSS to induce colitis. It is known that DSS can induce severe inflammation in mice characterized by persistent weight loss, rectal bleeding and diarrhea. As shown in Fig 1A, DSS-treated mice exhibited profound body weight loss, whereas AZD8055 attenuated the loss of body weight. By daily monitoring of clinical manifestations such as weight loss, diarrhea, and rectal bleeding, we scored disease activity index (DAI) according to the standards in Table 1. We observed that AZD8055 decreased DAI score and prevented colitis (Fig 1B). DSS-induced colon shortening, a marker of intestinal inflammation, was also ameliorated by AZD8055 (Fig 1C and 1D). The severity of intestinal inflammation and ulceration were further assessed by histological study using Hematoxylin & eosin (H&E) staining. DSS-induced pathological damage includes epithelial crypt loss, gross ulceration following massive infiltration of monocytic cells into the mucosa, as well as edema and congestion of the submucosa. As shown in Fig 1E and 1F, AZD8055-treated mice showed less inflammatory cells infiltration and smaller ulceration and greater mucosal integrity. Thus, we concluded that AZD8055 treatment could relieve DSS-induced colitis.

Results were from three independent experiments.

2. AZD8055 reduces pro-inflammatory mediator production in colon

The hallmark of DSS-induced colitis is the increased production of pro-inflammatory cytokines in the colon. The colon was isolated and real-time PCR was used to assess the expression profiles of pro-inflammatory cytokines. As shown in Fig 2, the mRNA levels of pro-inflammatory cytokines, such as IFN-γ, TNF-α, IL-1β, IL-17A and IL-6 in the colon increased in the presence of DSS administration, whereas AZD8055 treatment decreased the mRNA levels of these cytokines. And the anti-inflammatory cytokine IL-10 increased under AZD8055 treatment.

3. AZD8055 decreases the proportion of CD4+ T cells and CD8+ T cells in vivo

Aberrant immune response is responsible for chronic inflammatory diseases. CD4+ and CD8+ T cells played important role in inflammatory bowel disease. We isolated and prepared mononuclear cells of spleen, peripheral lymph nodes and peripheral blood from DSS-treated and DSS+AZD8055 treated mice. The results showed that, compared with DSS treatment, DSS +AZD8055 induced reduction in the number and proportion of CD4+ and CD8+ T cells, especially in the spleen and peripheral blood (Fig 3).
Fig 1. AZD8055 attenuates the development of intestinal inflammation. When the mice developed clinical signs of disease, they were sacrificed. (A) During the course of colitis, body weights were recorded and calculated as percentage of the initial weight at day 1 (n = 8 for AZD, n = 8 for control). (B) Disease activity index (DAI) of each group. (C) Gross morphology of each group. (D) The length of colon of each group. (E) Histological observations of colon sections with H&E staining (Original magnifications, 200×magnification). (F) Histological score of each group. All data represented the mean±SEM. Statistical significance was assessed by t-test. *P<0.05, **P<0.01.

doi:10.1371/journal.pone.0154564.g001
Fig 2. AZD8055 treatment suppresses the expression of pro-inflammatory mediators. (A-F) The expression profiles of IFN-γ, TNF-α, IL-1β, IL-6, IL-17A and IL-10 were determined in the colon of emulsifier or AZD8055-treated mice by real-time PCR. Data was normalized to the expression of HPRT mRNA (n = 8/group). All data represented the mean±SEM. Statistical significance was assessed by t-test. *P<0.05, **P<0.01.

doi:10.1371/journal.pone.0154564.g002
AZD8055 treatment leads to a decrease in the percentage of CD4+ T cells and CD8+ T cells in vivo. (A) The percentage of CD4+ T cells in the spleen, lymph nodes and peripheral blood of mice treated with AZD8055 or emulsifier. (B) The percentage of CD8+ T cells in the spleen, lymph nodes and peripheral blood of mice treated with AZD8055 or emulsifier. (C) The cell number of CD4+ T cells and CD8+ T cells in the spleen, lymph nodes and peripheral blood of mice treated with AZD8055 or emulsifier. All data represented the mean ± SEM. Statistical significance was assessed by t-test. *P<0.05, **P<0.01.

doi:10.1371/journal.pone.0154564.g003
4. AZD8055 suppresses the proliferation of CD4+ T cells and CD8+ T cells in vitro

As described above, AZD8055 decreased the percentage of CD4+ and CD8+ T cells in spleen, lymph nodes and peripheral blood. To further confirm the anti-inflammatory effect of AZD8055 in vitro, we investigated if AZD8055 inhibited the proliferation of CD4+ and CD8+ T cells. CFSE-labeled CD4+ and CD8+ T cells were activated with anti-CD3/CD28 beads in the presence or absence of increasing concentrations of AZD8055 (10–50nM). The proliferation of CD4+ and CD8+ T cells were analyzed by flow cytometry. As shown in Fig 4A and 4B, we saw that the proliferation of CD4+ and CD8+ T cells were inhibited by AZD8055 in a dose-dependent manner.

5. AZD8055 balances TH1/TH17/Treg profile in vivo

Through the activation of separate signaling pathways, naive T cells differentiate into helper T (TH) cells, termed TH1, TH2 and TH17, and induce Treg cells. Dysregulation of TH cells results in IBD. To test the effect of AZD8055 on the proportion of different T helper cell subsets in spleen, mesenteric lymph nodes and lamina propria, we isolated mononuclear cells of mesenteric lymph nodes and lamina propria from DSS-treated mice as well as DSS+AZD8055 treated mice. We found that, although there were no differences in splenic TH1, TH17 and Treg between the control and AZD8055 treated mice (Fig 5A), AZD8055 treatment reduced the proportion of TH1 cells (CD4+IFN-γ+) and TH17 cells (CD4+IL-17+) and increased the proportion of Treg cells (CD4+FOXP3+) in mesenteric lymph nodes and lamina propria (Fig 5B and 5C). In addition, the cell number of CD4+ T cells and CD8+ T cells in the presence of AZD8055 were also decreased in the mesenteric lymph nodes and lamina propria (Fig 5D). Therefore, AZD8055 ameliorated colitis might through balancing TH1/TH17/Treg cell profile to maintain normal immune homeostasis.

6. AZD8055 inhibits the proliferation and differentiation of TH1 and TH17 cells in vitro

Next, we determined if AZD8055 could restrain T cell expansion and differentiation in vitro. CFSE-labeled naive CD4+ T cells were isolated and irritated under TH0, TH1 and TH17 conditions for 4 days in the presence of AZD8055 at different concentration (0nM, 20nM, 50nM). We observed a dose-dependent inhibition of TH1 proliferation and differentiation by AZD8055. While there was a significant inhibitory effect of AZD8055 on TH1 cell differentiation at a concentration of 50nM (Fig 6A and 6C). And AZD8055 exhibited the inhibition on TH17 cell differentiation at a concentration of 20nM (Fig 6B and 6C).

7. AZD8055 enhances the proliferation and differentiation of Treg cells in vitro

Then, we evaluated whether AZD8055 could expand Treg cells from CD4+ T cells in vitro. CFSE-labeled naive CD4+ T cells were cultured in the presence of AZD8055 (0nM, 20nM) under Treg culture condition for 4 days. As shown in Fig 7, the population of CD4+Foxp3+ Treg cells was increased in the presence of AZD8055 at a concentration of 20nM, which might resulted in switching naive T cells differentiation into Treg cells. Consistently, AZD8055 also increased the proliferation of Treg cells at a concentration of 20nM.
AZD8055 inhibits the proliferation of CD4+ T cells and CD8+ T cells in vitro. CD4+ T cells and CD8+ T cells isolated from spleen and mesenteric lymph node of mice were stimulated with anti-CD3/CD28 and labeled with CFSE in the presence of AZD8055 (10–50nM) for two or three days. (A) The proliferation of CD4+ T cells in the presence of AZD8055 were examined by flow cytometry. (B) The proliferation of CD8+ T cells in the presence of AZD8055 were examined by flow cytometry. Results were from three independent experiments.

doi:10.1371/journal.pone.0154564.g004
Fig 5. AZD8055 inhibits TH1 and TH17 cell polarization and expands Treg cell polarization in vivo. Lymphocytes were isolated from the spleen, mesenteric lymph nodes and lamina propria and analyzed by flow cytometry on day7. (A) The percentage of TH1 cells (CD4+IFN-γ+), TH17 cells (CD4+IL-17+) and Treg cells (CD4+FOXP3+) in spleen treated with AZD8055 or emulsifier. (B) The percentage of TH1 cells, TH17 cells and Treg cells in mesenteric lymph nodes treated with AZD8055 or emulsifier. (C) The percentage of TH1 cells, TH17 cells and Treg cells in lamina propria treated with AZD8055 or emulsifier. (D) The cell number of CD4+ T cells and CD8+ T cells in the mesenteric lymph nodes and lamina propria treated with AZD8055 or emulsifier. The data were expressed as mean±SEM. Statistical significance was assessed by t-test. *P<0.05, **P<0.01.

doi:10.1371/journal.pone.0154564.g005
Fig 6. AZD8055 inhibits the proliferation and differentiation of naive CD4+ T cells in vitro. Naive CD4+ T cells were isolated from spleen and lymph nodes of mice, CFSE-labeled, and activated in the presence of AZD8055 (0nM, 20nM, 50nM) under TH0, TH1 and TH17 conditions for 4 days. (A) TH1 cells were activated with PMA + Ionomycin and stained for CD4 and intracellular expression of IFN-γ. Dot-plots showed the expression of CD4+ IFN-γ+ TH1 cells under TH0 condition (Upper panels). Dot-plots showed the differentiation of TH1 cells under TH1 condition (Middle panels). Scatterplot displayed the proliferation of TH1 cells.
Discussion

In this study, we found that ATP-competitive dual mTOR inhibitor AZD8055 ameliorated DSS-induced colitis by increasing the functional activity of Treg cells and suppressing TH1 and TH17 cell response in vivo. Previous studies have showed that infusion SCID mice with naive T cells without Treg cells induces hyperactivity to intestinal commensal bacteria, while infusing whole T cells prevents inflammation [34–36]. Another study also observed that the depletion of Treg cells in mice deteriorated the disease [37]. In the presence of Interleukin-23(IL-23) or Interleukin-6 (IL-6), naive T cells differentiate into TH17 cells [38, 39]. The efficacy of balancing Treg/TH17 cells has an important role in the clinical and experiment model [40–42]. Tocilizumab, a humanized monoclonal antibody against the membrane and the soluble IL-6, and Ustekinumab, a human monoclonal antibody that blocks IL-12 and IL-23, have been used to treat IBD patients [43, 44]. Hui Yin et al have found that sirolimus (Rapamycin analogue) ameliorated TNBS-induced colitis by promoting differentiation of Treg cells and inhibiting the generation of TH17 cells [45]. In our study, we found that AZD8055 had the dose-dependent effect on inhibition of TH17 cells differentiation, and increase of Treg cells proliferation and differentiation in vitro. Furthermore, we also found that AZD8055 treatment induced the increase of Treg cells and decrease of TH17 cells in the lamina propria and mesenteric lymph nodes in mice. Our results suggested that AZD8055 was involved in the regulation of balancing of Treg/TH17 cells both in vivo and in vitro.

Delgoffe et al reported that mTOR-deficient T cells were unable to differentiate into TH1, TH2, or TH17 effector cells while they displayed normal activation and IL-2 production upon initial stimulation [20]. The incapacity of differentiation was related to STAT activation reducing as well as failure of the up-regulation of lineage specific transcription factors. However, under normal conditions of activation, T cells lacking mTOR were capable of differentiating into Foxp3+regulatory T cells. The results indicated that mTOR pathway was critically involved in the differentiation of CD4+ effector T cells [46, 47]. The first-generation mTOR inhibitors Rapamycin and its analogues such as Sirolimus and Everolimus employed an allosteric mechanism to block mTORC1 output. Meanwhile, second generation mTOR inhibitors such as AZD8055 and PP242 competitively targeted the ATP binding site to hinder kinase activity of both TORC1 and TORC2 [48]. In our study, we found that AZD8055 could suppress the differentiation and proliferation of TH1 and TH17 cells and increase Treg cells both in vivo and in vitro.

Recent studies have found that specific B cell subsets, regulatory B cells (Bregs), are potent immune response regulators and are of crucial importance in a variety of mouse models of immune-mediated disorders like IBD, systemic lupus erythematos(SLE) and rheumatoid arthritis (RA) and immune thrombocytopenia patients(ITP) [49–53]. Flores-Borja et al. investigated that healthy Breg cells especially CD19+CD24hiCD38hi B cells could limit the differentiation of naïve T cells into TH1 and TH17 cells and convert effector CD4+ T cells into Treg cells by producing a large amount of IL-10 [54]. Ashour HM et al. studied that expansion of Breg cells were necessary for the induction of T cell tolerance elicited through the anterior chamber of the eye [55]. Therefore, Bregs may play an important role in the induction of T cell
AZD8055 expands the proliferation and differentiation of Treg cells in vitro. Naïve CD4+ T cells were isolated from spleen and lymph nodes of mice, CFSE-labeled, and activated in the presence of AZD8055 (0nM, 20nM) under TH0 and Treg conditions for 4 days. (A) Treg cells were permeabilized and stained for CD4 and intracellular expression of Foxp3 in the presence of AZD8055 (0nM, 20nM). Dot plots showed the differentiation of CD4+ Foxp3+ Treg cells under TH0 and Treg conditions (Upper panels). Scatterplot displayed the proliferation of Treg cells under TH0 and Treg conditions treated with AZD8055 (Lower panels). (B) Results were from three independent experiments. All results showed the mean±SEM. Statistical significance was evaluated by student’s t-test. *P<0.05, **P<0.01, ***P<0.005.

doi:10.1371/journal.pone.0154564.g007
tolerance and in maintaining the key balance between TH1/TH17/Treg populations [56]. In addition, it has also been shown that Granulocyte macrophage colony stimulating factor (GM-CSF) can differentiates precursor cells into tolerogenic DCs that can expand Treg cell numbers and function [57,58]. These Treg cells can suppress effector T cells through secretion of IL-10 [59]. GM-CSF has a critical role in regulating the immune response and maintaining immunological tolerance by inducing specialized cell types from precursors or by affecting phenotypes of mature cell populations [60–62]. The protective effect of GM-CSF has been investigated in IBD and Type 1 diabetes (T1D) [63–66]. Adoptive transfer of GM-CSF could directly expand Treg cells which was shown in diabetes in mouse models [66, 67]. Thus GM-CSF may exert a far-reaching influence on the state of immune tolerance referring to a wide array of autoimmune diseases.

It has been shown that Rapamycin inhibites induced chronic colitis by decreasing leukocyte migration. However, the effect of Rapamycin on T cells regulation has not been investigated. Since Rapamycin also inhibits mTORC2 activity after the prolonged treatment, it would be interesting to compare the efficiency of Rapamycin with AZD8055 in DSS-induced colitis. In our study, we showed that ATP-competitive dual mTOR inhibitor AZD8055 exhibited potent immunosuppressive properties and was used therapeutically in countering autoimmunity and preventing allograft rejection. In future studies, we will use mTORC1 or mTORC2 knockout mice to study the effect of mTOR complexes on DSS-induced mice. We will also investigate the effect of mTOR inhibition on the immune cells from human biopsy in IBD patients and explore possible mechanism.

Although AZD8055 has been used for its anti-tumor activity, its application in the autoimmune diseases still lacks comprehensive understanding [68–71]. The immune regulation of AZD8055 is involved in a variety of immune cells and cytokines. Our study showed that AZD8055 attenuated DSS-induced colitis and also explored its possible mechanisms in immune regulation. This study indicates that ATP-competitive mTOR inhibitor may offer a promising alternative pharmaceutical strategy to manage IBD.

Acknowledgments
The authors would like to thank Professor Yu Li (Shanghai Jiaotong University Medical School) for critical comments and help with the manuscript.

Author Contributions
Conceived and designed the experiments: J. Zhong RT. Performed the experiments: SRH MMC YLW. Analyzed the data: ZTW YFP RF XQL. Contributed reagents/materials/analysis tools: LW J. Zhou SCZ TYZ YL MCZ. Wrote the paper: SRH MMC.

References
1. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010; 28: 573–621. doi: 10.1146/annurev-immunol-030409-101225 PMID: 20192811
2. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006; 3: 390–407. PMID: 16819502
3. Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol. 2007; 102: 2058–2069. PMID: 17561966
4. Zenewicz LA, Antov A, Flavell RA. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med. 2009; 15: 199–207. doi: 10.1016/j.molmed.2009.03.002 PMID: 19362058
5. Elson CO, Cong Y, McCracken VJ, Dimmitt RA, Lorenz RG, Weaver CT. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev. 2005; 206: 260–276. PMID: 16048554
6. Makita S, Kanai T, Oshima S, Uraushihara K, Totsuka T, Sawada T, et al. CD4+CD25Bright T cells in human intestinal lamina propria as regulatory cells. J Immunol. 2004; 173: 3119–3130. PMID: 15322172

7. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev. 2006; 212: 256–271. PMID: 16903919

8. Annunziato F, Cosmi L, Santarassi V, Maggi L, Liotta F, Mazzinghi B, et al. Phenotypic and functional features of human Th17 cells. J Exp Med. 2007; 204: 1849–1861. PMID: 17635957

9. Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006; 116: 1310–1316. PMID: 16670770

10. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361: 2066–2078. doi: 10.1056/NEJMra0804647 PMID: 19923578

11. Wu X, Dou Y, Yang Y, Bian D, Luo J, Tong B, et al. Actigenin exerts anti-colitis efficacy through inhibiting the differentiation of Th1 and Th17 cells via an mTORC1-dependent pathway. Biochem Pharmacol. 2015; 96: 323–336. doi: 10.1016/j.bcp.2015.06.008 PMID: 26074264

12. Takedatsu H, Michelsen KS, Wei B, Landers CJ, Thomas LS, Dhall D, et al. TL1A (TNFSF15) Regulates the Development of Chronic Colitis by Modulating Both Th1 Helper 1 and Th17 Helper 1 Activation. Gastroenterology. 2008; 135: 552–567. doi: 10.1053/j.gastro.2008.04.037 PMID: 18598698

13. Heiseke AF, Faul AC, Lehr HA, Förster I, Schmid RM, Krug AB, et al. CCL17 Promotes Intestinal Inflammation in Mice and Counteracts Regulatory T Cell–Mediated Protection From Colitis. Gastroenterology. 2012; 142: 335–345. doi: 10.1053/j.gastro.2011.10.027 PMID: 22057112

14. Sokol H, Conway KL, Zhang M, Choi M, Morin B, Cao Z, et al. Card9 Mediates Intestinal Epithelial Cell Restitution, T Helper 17 Responses, and Control of Bacterial Infection in Mice. Gastroenterology. 2013; 145: 591–601. doi: 10.1053/j.gastro.2013.05.047 PMID: 23732773

15. Mudter J, Yu J, Zufferey C, Brüstle A, Wirtz S, Weigmann B, et al. IRF4 Regulates IL-17A Promoter Activity and Controls ROtcl dependent Th17 Colitis In Vivo. Inflamm Bowel Dis. 2011; 17: 1343–1358. doi: 10.1002/ibd.21375777

16. Brown JB, Chersh P, Zhang Z, Ryu H, Managlia E, Barrett T. P-selectin Glycoprotein Ligand-1 Is Needed for Sequential Recruitment of T-helper 1 (Th1) and Local Generation of Th17 Cells in Dextran Sodium Sulfate (DSS) Colitis. Inflamm Bowel Dis. 2012; 18: 323–332. doi: 10.1002/ibd.21779 PMID: 22009715

17. Ustyugova IV, Zhi L, Wu MX. Reciprocal Regulation of the Survival and Apoptosis of Th17 and Th1 Cells in the Colon. Inflamm Bowel Dis. 2012; 18: 333–343. doi: 10.1002/ibd.21772 PMID: 21618360

18. Wurbel MA, McIntire MG, Dwyer P, Fiebiger E. CCL25/CCR9 Interactions Regulate Large Intestinal Inflammation in a Murine Model of Acute Colitis. PLoS One. 2011; 6: e16442. doi: 10.1371/journal.pone.0016442 PMID: 21283540

19. Morgan ME, Zheng B, Koelink PJ, van de Kant HJ, Haazen LC, van Roest M, et al. New perspective on dextran sodium sulfate colitis: antigen-specific T cell development during intestinal inflammation. PLoS One. 2013; 8: e69936. doi: 10.1371/journal.pone.0069936 PMID: 23936123

20. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunol. 2009; 30: 832–844. doi: 10.1016/j.immuni.2009.04.014 PMID: 19538929

21. Shin HJ, Baker J, Leveson-Gower DB, Smith AT, Sega EI, Negrin RS. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+ Foxp3+ regulatory T cells. Blood. 2011; 118: 2342–2350. doi: 10.1182/blood-2010-10-313684 PMID: 21734238

22. Robb RJ, Lineburg KE, Kuns RD, Wilson YA, Raffelt NC, Olver SD, et al. Identification and expansion of highly suppressive CD8(+)FoxP3(+) regulatory T cells after experimental allogeneic bone marrow transplantation. Blood. 2012; 119: 5898–5908. doi: 10.1182/blood-2011-12-396119 PMID: 22538855

23. Farkas S, Hornung M, Sattler C, Guba M, Steinbauer M, Anthuber M, et al. Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis. Int J Colorectal Dis. 2006; 21: 747–753. PMID: 16228179

24. Matsuda C, Ito T, Song J, Mizushima T, Tamagawa H, Kai Y, et al. Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis. Clin Exp Immunol. 2007; 148: 348–359. PMID: 17437423

25. Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol. 2009; 9: 324–337. doi: 10.1038/nri2546 PMID: 19390566

26. Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol. 2012; 30: 39–68. doi: 10.1146/annurev-immunol-020711-075024 PMID: 22136167
27. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009; 284: 8023–8032. doi: 10.1074/jbc.M900301200 PMID: 19150980

28. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010; 70: 288–298. doi: 10.1158/0008-5472.CAN-09-1751 PMID: 20028854

29. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993; 69: 238–249. PMID: 8305599

30. ten Hove T, van den Blink B, Pronk I, Drillenburg P, Peppelenbosch MP, van Deventer SJ. Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis. Gut. 2002; 50: 507–512. PMID: 11889071

31. Atarashi K, Nishimura J, Shima T, Umesaki Y, Yamamoto M, Onoue M, et al. ATP drives lamina propria T(H)17 cell differentiation. Nature. 2008; 455: 808–812. doi: 10.1038/nature07240 PMID: 18716618

32. Chen Z, Kim SJ, Chamberlain ND, Pickens SR, Volin MV, Volkov S, et al. The novel role of IL-7 ligation to IL-7 receptor in myeloid cells of rheumatoid arthritis and collagen-induced arthritis. J Immunol. 2013; 190: 5256–5266. doi: 10.4049/jimmunol.1201675 PMID: 23606539

33. Bhattacharya P, Fan J, Haddad C, Eskioglu A, Reignier J, Elshabrawy HA, et al. A novel pancreatic β-cell targeting bispecific-antibody (BsAb) can prevent the development of type 1 diabetes in NOD mice. Curr Diab Rep. 2014; 14: 187–98. doi: 10.1007/s11892-014-0414-8 PMID: 24792135

34. Martin B, Banz A, Bienvenu B, Cordier C, Dautigny N, Bécourt C, et al. Suppression of CD4+ T lymphocyte effector functions by CD4+CD25+ cells in vivo. J Immunol. 2004; 172: 3391–3398. PMID: 15004137

35. Karlsson F, Robinson-Jackson SA, Gray L, Zhang S, Grisham MB. Ex vivo generation of regulatory T cells: characterization and therapeutic evaluation in a model of chronic colitis. Methods Mol Biol. 2011; 677: 47–61. doi: 10.1007/978-1-60761-869-0_4 PMID: 20941602

36. Martin B, Aurfray C, Delpoux A, Pommier A, Durand A, Charvet C, et al. Highly self-reactive naive CD4 T cells are prone to differentiate into regulatory T cells. Nat Commun. 2013; 4: 2209. doi: 10.1038/ ncomms2309 PMID: 23900386

37. Velatkamp C, Ruhrwald R, Giesem T, Autschbach F, Kaden I, Velatkamp R, et al. CD4+CD25+ cell depletion from the normal CD4+ T cell pool prevents tolerance toward the intestinal flora and leads to chronic colitis in immunodeficient mice. Inflamm Bowel Dis. 2006; 12: 437–446. PMID: 16775487

38. Kitani A, Xu L. Regulatory T cells and the induction of IL-17. Mucosal Immunol. 2008; Suppl 1: S43–46. doi: 10.1038/mi.2008.51 PMID: 19079228

39. Luckheeram RV, Zhou R, Verma AD, Xia B. CD4+ T cells: differentiation and functions. Clin Dev Immunol. 2012; 2012: 925135 doi: 10.1155/2012/925135 PMID: 22474485

40. Kleinewietfeld M, Hafler DA. The plasticity of human Treg and Th17 cells and its role in autoimmunity. Semin Immunol. 2013; 25: 305–312. doi: 10.1016/j.smim.2013.10.009 PMID: 24211039

41. O’Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med. 2004; 10: 801–805. PMID: 15286781

42. Ogino H, Nakamura K, Ihara E, Akiho H, Takayanagi R. CD4+CD25+ regulatory T cells suppress Th17-responses in an experimental colitis model. Dig Dis Sci. 2011; 56: 376–386. doi: 10.1007/s10620-010-1286-2 PMID: 20521112

43. Ito H. Treatment of Crohn’s disease with anti-IL-6 receptor antibody. J Gastroenterol. 2005; 40: S172. PMID: 15902961

44. Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanss J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012; 367: 1519–1528. doi: 10.1056/NEJMoa1203572 PMID: 23075178

45. Yin H, Li X, Jiang B, Liu T, Yuan B, Ni Q, et al. Sirolimus ameliorates inflammatory responses by switching the regulatory T/T helper type 17 profile in murine colitis. Immunology. 2013; 139: 494–502. doi: 10.1111/imm.12096 PMID: 23480027

46. Mondino A, Mueller DL. mTOR at the crossroads of T cell proliferation and tolerance. Semin Immunol. 2007; 19: 162–172. PMID: 17383196

47. Yurchenko E, Shio MT, Huang TC, Da Silva Martins M, Szyl M, Levings MK, et al. Inflammation-driven reprogramming of CD4+ Foxp3+ regulatory T cells into pathogenic Th1/Th17 T effectors is abrogated by mTOR inhibition in vivo. PLOS One. 2012; 7: e35572. doi: 10.1371/journal.pone.0035572 PMID: 22545118

48. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal. 2009; 2: pe24. doi: 10.1126/scisignal.267pe24 PMID: 19383975
49. Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, et al. CD19 +CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity. 2010; 32: 129–40. doi: 10.1016/j.immuni.2009.11.009 PMID: 20079667

50. Maseda D, Candando KM, Smith SH, Kalampokis I, Weaver CT, Plevy SE, et al. Peritoneal cavity regulatory B cells (B10 cells) modulate IFN-γ+CD4+ T cell numbers during colitis development in mice. J Immunol. 2013; 191: 2780–95. doi: 10.4049/jimmunol.1300649 PMID: 23918988

51. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol. 2010; 10: 236–47. doi: 10.1038/nri2729 PMID: 20224569

52. Salinas GF, Braza F, Brouard S, Tak PP, Baeten D. The role of B lymphocytes in the progression from autoimmunity to autoimmune disease. Clin Immunol. 2013; 146: 34–45. doi: 10.1016/j.clim.2012.10.005 PMID: 23202542

53. Hua F, Ji L, Zhan Y, Li F, Zou S, Chen L, et al. Aberrant frequency of IL-10-producing B cells and its association with Treg/Th17 in adult primary immune thrombocytopenia patients. Biomed Res Int. 2014; 2014:571302. doi: 10.1155/2014/571302 PMID: 25057496

54. Bhattacharya P, Gopisetty A, Ganesh BB, Sheng JR, Prabhakar BS. GM-CSF induced, bone-marrow-derived dendritic cells can expand natural Tregs and induce adaptive Tregs by different mechanisms. J Leukoc Biol. 2011; 89: 235–49. doi: 10.1189/jlb.0310154 PMID: 21048215

55. Gopisetty A, Bhattacharya P, Haddad C, Bruno JC Jr, Vasu C, Miele L, et al. OX40L/Jagged1 cosignaling by GM-CSF-induced bone marrow-derived dendritic cells is required for the expansion of functional regulatory T cells. J Immunol. 2013; 190: 5516–25. doi: 10.4049/jimmunol.1202298 PMID: 23630352

56. Gangi E, Vasu C, Cheatem D, Prabhakar BS. IL-10-producing CD4+CD25+ regulatory T cells play a critical role in granulocyte-macrophage colony stimulating factor-induced suppression of experimental autoimmune thyroiditis. J Immunol. 2005; 174: 7006–13. PMID: 15905543

57. Rowin J, Thiruppathi M, Arhebamen E, Sheng J, Prabhakar BS, Meriggioi MN. Granulocyte macrophage colony stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve. 2012; 46: 449–53. doi: 10.1002/mus.23488 PMID: 22907239

58. Bhattacharya P, Thiruppathi M, Elshabrawy HA, Alhashwai K, Kumar P, Prabhakar BS. GM-CSF: An immune modulatory cytokine that can suppress autoimmune. Cytokine. 2015; 75: 261–71. doi: 10.1016/j.cyto.2015.03.030 PMID: 26113402

59. Bhattacharya P, Budnick I, Singh M, Thiruppathi M, Alhashwai K, Elshabrawy H, et al. Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy. J Interferon Cytokine Res. 2015; 35: 585–99. doi: 10.1089/jir.2014.0149 PMID: 25803788

60. Bemasconi E, Favre L, Maillard MH, Bachmann D, Pyhoud C, Bouzourene H, et al. Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing. Inflamm Bowel Dis. 2010; 16: 428–41. doi: 10.1002/ibd.21072 PMID: 19639560

61. Sainathan SK, Hanna EM, Gong Q, Bishnupuri KS, Luo Q, Colonna M, et al. Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis. Inflamm Bowel Dis. 2008; 14: 88–99. PMID: 17932977

62. Gathungu G, Kim MO, Ferguson JP, Sharma Y, Zhang W, Ng SM, et al. Granulocyte-macrophage colony-stimulating factor autoantibodies: a marker of aggressive Crohn’s disease. Inflamm Bowel Dis. 2013; 19: 1671–80. doi: 10.1097/MIB.0b013e3182815006 PMID: 23749272

63. Gaudreau S, Guindi C, Menard M, Besin G, Dupuis G, Amrani A. Granulocyte macrophage colony-stimulating factor prevents diabetes development in NOD mice by inducing tolerogenic dendritic cells that sustain the suppressive function of CD4+CD25+ regulatory T cells. J Immunol. 2007; 179: 3638–47. PMID: 17785799

64. Kared H, Leforban B, Montandon R, Renand A, Layseca Espinosa E, Chatenoud L, et al. Role of GM-CSF in tolerance induction by mobilized hematopoietic progenitors. Blood. 2008; 112: 2575–8. doi: 10.1182/blood-2008-02-140681 PMID: 18617837
68. Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia. 2012; 26: 1195–202. doi: 10.1038/leu.2011.339 PMID: 22143671

69. Li Q, Song XM, Ji YY, Jiang H, Xu LG. The dual mTORC1 and mTORC2 inhibitor AZD8055 inhibits head and neck squamous cell carcinoma cell growth in vivo and in vitro. Biochem Biophys Res Commun. 2013; 440: 701–706. doi: 10.1016/j.bbrc.2013.09.130 PMID: 24103749

70. Sini P, James D, Chresta C, Guichard S. Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells. Autophagy. 2010; 6: 553–554. doi: 10.4161/auto.6.4.11671 PMID: 20364113

71. Rosborough BR, Raich-Regue D, Liu Q, Venkataramanan R, Turnquist HR, Thomson AW. Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection. Am J Transplant. 2014; 14: 2173–2180. doi: 10.1111/ajt.12799 PMID: 25307040